Compare TRMK & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRMK | IRON |
|---|---|---|
| Founded | 1889 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 1994 | 2020 |
| Metric | TRMK | IRON |
|---|---|---|
| Price | $42.93 | $69.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $44.50 | ★ $103.18 |
| AVG Volume (30 Days) | 292.5K | ★ 432.1K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | ★ 1.93 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.82 | N/A |
| Revenue Next Year | $4.86 | $283.52 |
| P/E Ratio | $46.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.39 | $40.00 |
| 52 Week High | $45.99 | $99.50 |
| Indicator | TRMK | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 54.30 |
| Support Level | $38.73 | $64.39 |
| Resistance Level | $43.29 | $71.53 |
| Average True Range (ATR) | 0.87 | 3.20 |
| MACD | -0.12 | 0.20 |
| Stochastic Oscillator | 8.47 | 72.29 |
Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.